These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 38869287)

  • 1. Comparison of SARS-CoV-2 seroprevalence estimates between commercial lab serum specimens and blood donor specimens, United States, September-December 2021.
    Kao S-YZ; Nycz E; Benoit TJ; Clarke KEN; Jones JM
    Microbiol Spectr; 2024 Aug; 12(8):e0012324. PubMed ID: 38869287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Based on Blood Donations, July 2020-May 2021.
    Jones JM; Stone M; Sulaeman H; Fink RV; Dave H; Levy ME; Di Germanio C; Green V; Notari E; Saa P; Biggerstaff BJ; Strauss D; Kessler D; Vassallo R; Reik R; Rossmann S; Destree M; Nguyen KA; Sayers M; Lough C; Bougie DW; Ritter M; Latoni G; Weales B; Sime S; Gorlin J; Brown NE; Gould CV; Berney K; Benoit TJ; Miller MJ; Freeman D; Kartik D; Fry AM; Azziz-Baumgartner E; Hall AJ; MacNeil A; Gundlapalli AV; Basavaraju SV; Gerber SI; Patton ME; Custer B; Williamson P; Simmons G; Thornburg NJ; Kleinman S; Stramer SL; Opsomer J; Busch MP
    JAMA; 2021 Oct; 326(14):1400-1409. PubMed ID: 34473201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 Antibody Testing in Health Care Workers: A Comparison of the Clinical Performance of Three Commercially Available Antibody Assays.
    Allen N; Brady M; Carrion Martin AI; Domegan L; Walsh C; Houlihan E; Kerr C; Doherty L; King J; Doheny M; Griffin D; Molloy M; Dunne J; Crowley V; Holmes P; Keogh E; Naughton S; Kelly M; O'Rourke F; Lynagh Y; Crowley B; de Gascun C; Holder P; Bergin C; Fleming C; Ni Riain U; Conlon N;
    Microbiol Spectr; 2021 Oct; 9(2):e0039121. PubMed ID: 34585976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating SARS-CoV-2 Seroprevalence in Canadian Blood Donors, April 2020 to March 2021: Improving Accuracy with Multiple Assays.
    Tuite AR; Fisman D; Abe KT; Rathod B; Pasculescu A; Colwill K; Gingras AC; Yi QL; O'Brien SF; Drews SJ
    Microbiol Spectr; 2022 Feb; 10(1):e0256321. PubMed ID: 35196819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 Virus-Like Particle Neutralizing Capacity in Blood Donors Depends on Serological Profile and Donor-Declared SARS-CoV-2 Vaccination History.
    Drews SJ; Hu Q; Samson R; Abe KT; Rathod B; Colwill K; Gingras AC; Yi QL; O'Brien SF
    Microbiol Spectr; 2022 Feb; 10(1):e0226221. PubMed ID: 35171006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 Seroprevalence Survey Estimates Are Affected by Anti-Nucleocapsid Antibody Decline.
    Bolotin S; Tran V; Osman S; Brown KA; Buchan SA; Joh E; Deeks SL; Allen VG
    J Infect Dis; 2021 Apr; 223(8):1334-1338. PubMed ID: 33400794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.
    Bajema KL; Wiegand RE; Cuffe K; Patel SV; Iachan R; Lim T; Lee A; Moyse D; Havers FP; Harding L; Fry AM; Hall AJ; Martin K; Biel M; Deng Y; Meyer WA; Mathur M; Kyle T; Gundlapalli AV; Thornburg NJ; Petersen LR; Edens C
    JAMA Intern Med; 2021 Apr; 181(4):450-460. PubMed ID: 33231628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies.
    Fenwick C; Croxatto A; Coste AT; Pojer F; André C; Pellaton C; Farina A; Campos J; Hacker D; Lau K; Bosch BJ; Gonseth Nussle S; Bochud M; D'Acremont V; Trono D; Greub G; Pantaleo G
    J Virol; 2021 Jan; 95(3):. PubMed ID: 33144321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population-Weighted Seroprevalence From Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, Vaccination, and Hybrid Immunity Among US Blood Donations From January to December 2021.
    Busch MP; Stramer SL; Stone M; Yu EA; Grebe E; Notari E; Saa P; Ferg R; Manrique IM; Weil N; Fink RV; Levy ME; Green V; Cyrus S; Williamson PC; Haynes J; Groves J; Krysztof D; Custer B; Kleinman S; Biggerstaff BJ; Opsomer JD; Jones JM
    Clin Infect Dis; 2022 Oct; 75(Suppl 2):S254-S263. PubMed ID: 35684973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Ortho VITROS and Roche Elecsys S and NC Immunoassays for SARS-CoV-2 Serosurveillance Applications.
    Sulaeman H; Grebe E; Dave H; McCann L; Di Germanio C; Sanghavi A; Sclar V; Bougie DW; Chatelain G; Biggerstaff BJ; Jones JM; Thornburg NJ; Kleinman S; Stone M; Busch MP
    Microbiol Spectr; 2023 Aug; 11(4):e0323422. PubMed ID: 37347180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changing Patterns of SARS-CoV-2 Seroprevalence among Canadian Blood Donors during the Vaccine Era.
    Reedman CN; Drews SJ; Yi QL; Pambrun C; O'Brien SF
    Microbiol Spectr; 2022 Apr; 10(2):e0033922. PubMed ID: 35412385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the SARS-CoV-2 antibody landscape in Norway in the late summer of 2022: high seroprevalence in all age groups with patterns of primary Omicron infection in children and hybrid immunity in adults.
    Tunheim G; Fossum E; Robertson AH; Rø GØI; Chopra A; Vaage JT; Vikse EL; Kran AB; Magnus P; Trogstad L; Mjaaland S; Hungnes O; Lund-Johansen F
    BMC Infect Dis; 2024 Aug; 24(1):841. PubMed ID: 39164637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The seroprevalence of SARS-CoV-2-specific antibodies in Australian children: A cross-sectional study.
    Koirala A; McRae J; Britton PN; Downes M; Prasad SA; Nicholson S; Winkler NE; O'Sullivan MVN; Gondalwala F; Castellano C; Carey E; Hendry A; Crawford N; Wadia U; Richmond P; Marshall HS; Clark JE; Francis JR; Carr J; Bartlett A; McMullan B; Skowno J; Hannah D; Davidson A; von Ungern-Sternberg BS; Lee-Archer P; Burgoyne LL; Waugh EB; Carlin JB; Naing Z; Kerly N; McMinn A; Hunter G; Heath C; D'Angelo N; Finucane C; Francis LA; Dougherty S; Rawlinson W; Karapanagiotidis T; Cain N; Brizuela R; Blyth CC; Wood N; Macartney K
    PLoS One; 2024; 19(9):e0300555. PubMed ID: 39292730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Multiplex Noninvasive Salivary Antibody Assay for SARS-CoV-2 Infection and Its Application in a Population-Based Survey by Mail.
    Egorov AI; Griffin SM; Fuzawa M; Kobylanski J; Grindstaff R; Padgett W; Simmons S; Hallinger DR; Styles JN; Wickersham L; Sams E; Hudgens E; Wade TJ
    Microbiol Spectr; 2021 Oct; 9(2):e0069321. PubMed ID: 34523986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence: Navigating the absence of a gold standard.
    Saeed S; O'Brien SF; Abe K; Yi QL; Rathod B; Wang J; Fazel-Zarandi M; Tuite A; Fisman D; Wood H; Colwill K; Gingras AC; Drews SJ
    PLoS One; 2021; 16(9):e0257743. PubMed ID: 34555095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential COVID-19 case ascertainment by age and vaccination status in Victoria, Australia: a serosurveillance and record linkage study.
    Szanyi J; Price DJ; Carville KS; Batty M; Yallop S; Nicholson S; Karapanagiotidis T; Rowe S; Sullivan S; Menon V; West D; Manoharan L; Copsey E; Majumdar SS; Sutton B; Williamson DA; McVernon J
    Commun Dis Intell (2018); 2024 Aug; 48():. PubMed ID: 39165016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of US Blood Donors Testing Reactive for Antibodies to SARS-CoV-2 Prior to the Availability of Authorized Vaccines.
    Dodd RY; Spencer BR; Xu M; Foster GA; Saá P; Brodsky JP; Stramer SL
    Transfus Med Rev; 2021 Jul; 35(3):1-7. PubMed ID: 34373145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 outbreak in Milan.
    Valenti L; Bergna A; Pelusi S; Facciotti F; Lai A; Tarkowski M; Lombardi A; Berzuini A; Caprioli F; Santoro L; Baselli G; Ventura CD; Erba E; Bosari S; Galli M; Zehender G; Prati D;
    Blood Transfus; 2021 May; 19(3):181-189. PubMed ID: 33539289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progression and Predictors of SARS-CoV-2 Antibody Seroreactivity In US Blood Donors.
    Vassallo RR; Dumont LJ; Bravo MD; Hazegh K; Kamel H
    Transfus Med Rev; 2021 Jul; 35(3):8-15. PubMed ID: 34376289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Serological Snapshot of COVID-19 Initial Stages in Israel by a 6-Plex Antigen Array.
    Fisher M; Levy H; Fatelevich E; Afrimov Y; Ben-Shmuel A; Rosenfeld R; Noy-Porat T; Glinert I; Sittner A; Biber A; Belkin A; Bar-David E; Puni R; Levy I; Mazor O; Weiss S; Mechaly A
    Microbiol Spectr; 2021 Oct; 9(2):e0087021. PubMed ID: 34612689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.